Oral Insulin Delivery in Diabetic Rats by PLGA Nanoparticles Combined with a Protease Inhibitor (N-Ethylmaleimide)

A. Faheem, D. Abdelkader, M. Osman, P. McCarron, S. El-Gizawy
{"title":"Oral Insulin Delivery in Diabetic Rats by PLGA Nanoparticles Combined with a Protease Inhibitor (N-Ethylmaleimide)","authors":"A. Faheem, D. Abdelkader, M. Osman, P. McCarron, S. El-Gizawy","doi":"10.5920/BJPHARM.588","DOIUrl":null,"url":null,"abstract":"Nanoparticles have shown a certain potential to overcome thedrawbacks of oral peptide delivery in the gastrointestinal tract such as lowpeptide stability and permeability. Insulin PLGA NP were prepared using amodified double emulsion solvent evaporation technique. Insulin PLGA NP were composedfrom human insulin (5 mg) encapsulated in PLGA 2.5% (w/v) mixed with PEG (2kDa, 5% w/w) and the external aqueous phase contained 1.25% of PVA. Theresulting nanoparticles of 202.6 nm diameter and loaded with 33.86 μg insulinper mg of polymer were utilised in this study to examine the hypoglycaemiceffect after combination with a protease inhibitor, N-Ethylmaleimide.","PeriodicalId":9253,"journal":{"name":"British Journal of Pharmacy","volume":"83 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5920/BJPHARM.588","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Nanoparticles have shown a certain potential to overcome thedrawbacks of oral peptide delivery in the gastrointestinal tract such as lowpeptide stability and permeability. Insulin PLGA NP were prepared using amodified double emulsion solvent evaporation technique. Insulin PLGA NP were composedfrom human insulin (5 mg) encapsulated in PLGA 2.5% (w/v) mixed with PEG (2kDa, 5% w/w) and the external aqueous phase contained 1.25% of PVA. Theresulting nanoparticles of 202.6 nm diameter and loaded with 33.86 μg insulinper mg of polymer were utilised in this study to examine the hypoglycaemiceffect after combination with a protease inhibitor, N-Ethylmaleimide.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PLGA纳米颗粒联合蛋白酶抑制剂(n -乙基马来酰亚胺)给药糖尿病大鼠口服胰岛素
纳米颗粒已经显示出一定的潜力来克服口服肽在胃肠道中递送的缺点,如肽的低稳定性和渗透性。采用改进的双乳溶剂蒸发技术制备胰岛素PLGA NP。胰岛素PLGA NP由人胰岛素(5mg)包封在PLGA 2.5% (w/v)中,与PEG (2kDa, 5% w/w)混合,外水相含有1.25%的PVA组成。该纳米颗粒直径为202.6 nm,负载33.86 μg / mg的聚合物,在本研究中研究了与蛋白酶抑制剂n -乙基马来酰亚胺联合使用后的降糖效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Case Law: A Review of Selected Pharmaceutical Patents Litigated in the UK Courts during 2022 Ensuring Pharmaceutical Product Success through Excipient QbD Efforts Solubility Enhancement for Dietheyldithiocarbamate-Zinc for Lung Cancer Treatment Impact of Critical Material Attributes of HPMC on the Release of Gliclazide from Hydrophilic Matrix Tablets Comparative Evaluation of the Disintegrant Properties of Starches from Three Cultivars of Dioscorea rotundata (Poir)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1